The AVANT GUARD clinical trial will evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation System as a first-line treatment for persistent atrial fibrillation, the only trial to study the use of PFA as frontline therapy in patients with this form of AF.